Angiosarcoma clinical trials at UCSF

2 research studies open to eligible people

Angiosarcoma is a rare cancer that starts in the cells that line blood vessels. UCSF is testing new personalized drugs given before surgery to see how tumors respond. UCSF is also studying an injected virus therapy with an immune drug to check safety and response.

Showing trials for

  • I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    open to eligible people ages 18 years and up

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

    San Francisco, California and other locations

  • Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

    open to eligible people ages 18 years and up

    This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.

    San Francisco, California

Our lead scientists for Angiosarcoma research studies include .

Last updated: